Therefore, reduction of estrogen levels by inhibiting estrogen biosynthesis with aromatase inhibitor and/or blockage of E2/ERα-mediated signaling pathways with selective ER modulators or selective ER down-regulator have become an integral part of the management of hormone-dependent and ERα-positive breast cancer [21, 22]. This evidence concerns the gene ESR1 and breast cancer.